Chemistry:Astegolimab
From HandWiki
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | AMG282; AMG-282 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Astegolimab is a selective ST2 IgG2 monoclonal antibody developed to treat asthma and chronic obstructive pulmonary disease. It is developed by Genentech.[1][2][3][4][5][6]
References
- ↑ Sperinde, Gizette; Dolton, Michael; Zhang, Wenhui; Mathews, Joel; Putnam, Wendy; Fischer, Saloumeh K (November 2023). "Factors contributing to the nonlinear pharmacokinetics of astegolimab: a close examination of potential causes". Bioanalysis 15 (21): 1305–1314. doi:10.4155/bio-2023-0115. PMID 37791725.
- ↑ Waters, Michael; McKinnell, James A.; Kalil, Andre C.; Martin, Greg S.; Buchman, Timothy G.; Theess, Wiebke; Yang, Xiaoying; Lekkerkerker, Annemarie N. et al. (January 2023). "Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial*". Critical Care Medicine 51 (1): 103–116. doi:10.1097/CCM.0000000000005716. ISSN 0090-3493. PMID 36519984.
- ↑ Kotani, Naoki; Dolton, Michael; Svensson, Robin J.; Ribbing, Jakob; Friberg, Lena E.; Vadhavkar, Shweta; Cheung, Dorothy; Staton, Tracy et al. (July 2022). "Population Pharmacokinetics and Exposure‐Response Relationships of Astegolimab in Patients With Severe Asthma" (in en). The Journal of Clinical Pharmacology 62 (7): 905–917. doi:10.1002/jcph.2021. ISSN 0091-2700. PMID 34964491. PMC 9303772. https://doi.org/10.1002/jcph.2021.
- ↑ Maurer, Marcus; Cheung, Dorothy S.; Theess, Wiebke; Yang, Xiaoying; Dolton, Michael; Guttman, Anna; Choy, David F.; Dash, Ajit et al. (December 2022). "Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis". Journal of Allergy and Clinical Immunology 150 (6): 1517–1524. doi:10.1016/j.jaci.2022.08.015. PMID 36041655.
- ↑ Yousuf, Ahmed J; Mohammed, Seid; Carr, Liesl; Yavari Ramsheh, Mohammadali; Micieli, Claudia; Mistry, Vijay; Haldar, Kairobi; Wright, Adam et al. (May 2022). "Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial". The Lancet Respiratory Medicine 10 (5): 469–477. doi:10.1016/S2213-2600(21)00556-7. PMID 35339234.
- ↑ Kelsen, Steven G.; Agache, Ioana O.; Soong, Weily; Israel, Elliot; Chupp, Geoffrey L.; Cheung, Dorothy S.; Theess, Wiebke; Yang, Xiaoying et al. (September 2021). "Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial". Journal of Allergy and Clinical Immunology 148 (3): 790–798. doi:10.1016/j.jaci.2021.03.044. PMID 33872652.
 |  |
